QTERN
PeakNDAORALTABLET
Approved
Feb 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QTERN is an oral small-molecule tablet approved by the FDA in February 2017 under sponsor AstraZeneca. The specific indication and mechanism of action are not disclosed in available data; however, the product is classified as a small-molecule NDA. Patient population and therapeutic mechanism require additional clinical source documentation.
$2MPart D
Peak4.1 years to LOEProduct is in peak commercial phase with modest Medicare Part D utilization (~2K claims in 2023), indicating mature market penetration with stable, potentially niche patient base.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance
Started Dec 2021
679 enrolled
Type 2 Diabetes Mellitus
Why This Matters for Your Career
Worked on QTERN at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.